TABLE 1.
Baseline patient characteristics
| Characteristic | Overall (N=33) | 180 mcg (N=14) | 120 mcg (N=19) | p |
|---|---|---|---|---|
| Age, y (range) | 40 (20, 64) | 44.1 (23, 64) | 37.1 (20, 64) | 0.11 |
| Male, n (%) | 22 (66.7) | 15 (78.9) | 7 (50.0) | 0.14 |
| Race, n (%) | — | — | — | 0.19 |
| White | 13 (39.4) | 8 (57.1) | 5 (26.3) | — |
| Black | 1 (3.0) | 0 | 1 (5.3) | — |
| Pacific Islander | 4 (12.1) | 2 (14.3) | 2 (10.5) | — |
| Other | 15 (45.5) | 4 (28.6 | 11 (57.9) | — |
| BMI, kg/m2 (range) | 26.4 (14.4, 36.6) | 25.9 (14.4, 36.5) | 26.7 (20.4, 36.6) | 0.69 |
| Prior Interferon Use (%) | 16 (48.5) | 6 (42.9) | 10 (52.6) | 0.58 |
| Patients with Cirrhosis (%) | 3 (9%) | 2 (6%) | 1 (3%) | 0.71 |
| Liver stiffness, kPa (range) | 11.7 (4.6, 27.4) | 12.7 (4.6, 27.4) | 11.0 (7.1,17.3) | 0.32 |
| HDV RNA, log10 IU/mL (range)a | 4.03 (0.5, 7.3) | 3.86 (0.5, 7.3) | 4.15 (0.5, 6.1) | 0.66 |
| ALT, U/mL (range)b | 105.6 (35, 364) | 94.7 (35, 197) | 113.6 (47, 364) | 0.35 |
| Total Bilirubin, mcmol/L (range)b | 8.6 (3, 20) | 7.8 (4, 14) | 9.2 (3, 20) | 0.27 |
| Albumin, g/L (range)b | 43.8 (37, 52) | 44.2 (41, 49) | 43.5 (37, 52) | 0.47 |
| INR (range)b | 1.2 (1.0, 1.6) | 1.2 (1.1, 1.4) | 1.3 (1.0, 1.6) | 0.49 |
| Platelets, ×109/L (range)b | 183.2 (95, 303) | 168.9 (95, 303) | 193.7 (104, 281) | 0.23 |
a
RoboGene HDV RNA Quantification Kit 2.0 assay: lower limit of quantitation=14 IU/mL; lower limit of detection=6 IU/mL.
b
Normal ranges: ALT=10–35 U/mL (female); 10–50 U/mL (male); total bilirubin=1.71–20.5 mcmol/L; albumin=35–55 g/L; INR=≤1.1; platelets=150–400×109/L.
Abbreviations: ALT, alanine aminotransferase; BMI, body mass index; INR, international normalized ratio.